Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D. Devillier R, et al. Among authors: demur c. Oncotarget. 2015 Apr 10;6(10):8388-96. doi: 10.18632/oncotarget.3460. Oncotarget. 2015. PMID: 25860933 Free PMC article.
Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
LaRochelle O, Bertoli S, Vergez F, Sarry JE, Mansat-De Mas V, Dobbelstein S, Dastugue N, Strzelecki AC, Cavelier C, Creancier L, Pillon A, Kruczynski A, Demur C, Sarry A, Huguet F, Huynh A, Récher C, Delabesse E. LaRochelle O, et al. Among authors: demur c. Oncotarget. 2011 Nov;2(11):850-61. doi: 10.18632/oncotarget.347. Oncotarget. 2011. PMID: 22081665 Free PMC article.
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S, Boutzen H, David L, Larrue C, Vergez F, Fernandez-Vidal A, Yuan L, Hospital MA, Tamburini J, Demur C, Delabesse E, Saland E, Sarry JE, Galcera MO, Mansat-De Mas V, Didier C, Dozier C, Récher C, Manenti S. Bertoli S, et al. Among authors: demur c. Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706. Oncotarget. 2015. PMID: 26515730 Free PMC article.
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.
Bertoli S, Bérard E, Huguet F, Huynh A, Tavitian S, Vergez F, Dobbelstein S, Dastugue N, Mansat-De Mas V, Delabesse E, Duchayne E, Demur C, Sarry A, Lauwers-Cances V, Laurent G, Attal M, Récher C. Bertoli S, et al. Among authors: demur c. Blood. 2013 Apr 4;121(14):2618-26. doi: 10.1182/blood-2012-09-454553. Epub 2013 Jan 30. Blood. 2013. PMID: 23365464 Free article.
Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.
De Clara E, Gourvest M, Ma H, Vergez F, Tosolini M, Dejean S, Demur C, Delabesse E, Recher C, Touriol C, Martelli MP, Falini B, Brousset P, Bousquet M. De Clara E, et al. Among authors: demur c. Haematologica. 2017 Oct;102(10):1718-1726. doi: 10.3324/haematol.2017.171645. Epub 2017 Jul 4. Haematologica. 2017. PMID: 28679652 Free PMC article.
mTOR, a new therapeutic target in acute myeloid leukemia.
Récher C, Dos Santos C, Demur C, Payrastre B. Récher C, et al. Among authors: demur c. Cell Cycle. 2005 Nov;4(11):1540-9. doi: 10.4161/cc.4.11.2159. Epub 2005 Nov 8. Cell Cycle. 2005. PMID: 16205124 Review.
80 results